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Cell Therapy Using Human Induced Pluripotent Stem
Cell-Derived Renal Progenitors Ameliorates Acute
Kidney Injury in Mice
TAKAFUMI TOYOHARA,a SHIN-ICHI MAE,a SHIN-ICHI SUETA,a TATSUYUKI INOUE,a YUKIKO YAMAGISHI,b
TATSUYA KAWAMOTO,b TOMOKO KASAHARA,a AZUSA HOSHINA,a TARO TOYODA,a HIROMI TANAKA,a
TOSHIKAZU ARAOKA,a AIKO SATO-OTSUBO,c KAZUTOSHI TAKAHASHI,a YASUNORI SATO,d
NOBORU YAMAJI,b SEISHI OGAWA,c SHINYA YAMANAKA,a,e KENJI OSAFUNEa
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ABSTRACT
Acute kidney injury (AKI) is defined as a rapid loss of renal function resulting from various etiologies,
with amortality rate exceeding 60%among intensive care patients. Because conventional treatments
have failed to alleviate this condition, the development of regenerative therapies using human
induced pluripotent stem cells (hiPSCs) presents a promising new therapeutic option for AKI. We
describe our methodology for generating renal progenitors from hiPSCs that show potential in ame-
liorating AKI.We established amultistep differentiation protocol for inducing hiPSCs into OSR1+SIX2+
renal progenitors capableof reconstituting three-dimensional proximal renal tubule-like structures in
vitro and in vivo. Moreover, we found that renal subcapsular transplantation of hiPSC-derived renal
progenitors ameliorated the AKI in mice induced by ischemia/reperfusion injury, significantly sup-
pressing the elevation of blood urea nitrogen and serum creatinine levels and attenuating histopath-
ological changes, such as tubular necrosis, tubule dilatationwith casts, and interstitial fibrosis. To our
knowledge, few reports demonstrating the therapeutic efficacy of cell therapy with renal lineage
cells generated from hiPSCs have been published. Our results suggest that regenerative medicine
strategies for kidney diseases could be developed using hiPSC-derived renal cells. STEM CELLS
TRANSLATIONAL MEDICINE 2015;4:980–992
SIGNIFICANCE
This report is the first to demonstrate that the transplantation of renal progenitor cells differentiated
from human induced pluripotent stem (iPS) cells has therapeutic effectiveness in mouse models of
acute kidney injury induced by ischemia/reperfusion injury. In addition, this report clearly demon-
strates that the therapeutic benefits come from trophic effects by the renal progenitor cells, and
it identifies the renoprotective factors secreted by the progenitors. The results of this study indicate
the feasibility of developing regenerative medicine strategy using iPS cells against renal diseases.
INTRODUCTION
Embryonic nephron progenitors have the capac-
ity to differentiate into nephron-forming glo-
merular and renal tubular epithelia [1, 2]. The
previous lineage tracing analyses verified that
nephron progenitors exist in the metanephric
mesenchyme derived from the intermediate me-
soderm (IM) [2, 3].Odd-skipped related 1 (Osr1) is
one of the earliest markers specific for the IM
[3–5].We previously generated OSR1-green fluo-
rescent protein (GFP) knock-in human induced
pluripotent stemcell (hiPSC) lines by homologous
recombination using bacterial artificial chro-
mosome (BAC)-based vectors, and established
robust methods for inducing OSR1+ IM cells using
growth factors and small molecules [6, 7].
Osr1 is continuously expressed from the IM
through nephron progenitors, although the
expression also extends into the lateral plate
mesoderm in early-stage mouse, chick, and
fish embryos [3–5]. Another lineage analysis
revealed that a homeodomain transcriptional
regulator, Six2, is required to maintain a neph-
ron progenitor population, ensuring the de-
velopment of a full complement constituting
nephrons. However, Six2 is also expressed in
other fetal organs, such as the skeletal muscle,
limbs, heart, eyes, and middle ears [2, 8]. Osr1
and Six2 interact synergistically to maintain
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nephron progenitor cells during kidney organogenesis [9].
Therefore, the combination of Osr1 and Six2 can be used as
a marker to more specifically define nephron progenitors.
AKI results in a highmortality rate, especially in intensive care
patients, with amortality rate of more than 60% [10]. In addition,
AKI has been reported as a cause of chronic kidney disease and
a risk factor for cardiovascular diseases [11]. Despite the urgent
need, the treatments for AKI remain to be developed [12]. Re-
cently, human fetal nephron progenitor cells have been shown
to participate in the repair of renal tissue in experimental animal
models of renal failure [13], suggesting that nephron progenitors
generated from hiPSCs could be used for the development of re-
generativemedicine against renal diseases. However, few studies
have demonstrated to date the therapeutic effects of hiPSC-
derived renal lineage cells against kidney disease [14].
In the present study, we established a protocol for differenti-
atinghiPSCs intoOSR1+SIX2+ renal progenitors that have thedevel-
opmental potential to differentiate and form three-dimensional
proximal renal tubule-like structures. Furthermore,weestablished
a method for transplanting hiPSC-derived renal progenitors into
the renal subcapsule, which ameliorated AKI in mice.
MATERIALS AND METHODS
Cell Culture
Cell cultures were performed as described previously [6, 7]. hiPSCs
(585A1,585B1,604A1,604B1,648A1,648B1,692D2,606A1,606B1,
610B1, 201B6, 201B7, 253G1 and 253G4) [15–18] and human em-
bryonic stem cells (hESCs) (khES1, khES3, and H9) [19, 20] were
grown on feeder layers of mitomycin C-treated mouse embryonic
fibroblasts derived from embryonic day (E) 12.5 ICR mouse em-
bryos or SNL feeder cells in medium containing primate ES medium
(ReproCELL, Yokohama, Japan, http://www.reprocell.com) supple-
mented with 500 U/ml penicillin/streptomycin (PS; Invitrogen,
Carlsbad, CA, http://www.invitrogen.com)and4or5ng/ml recombi-
nant human basic fibroblast growth factor (Wako Chemical, Osaka,
Japan, http://www.wako-chem.co.jp/english). For routine passag-
ing, the hiPSC/ESC colonies were dissociated by an enzymatic
method with CTK dissociation solution consisting of 0.25% trypsin
(Invitrogen), 0.1% collagenase IV (Invitrogen), 20% knockout serum
replacement (KSR, Invitrogen), and 1 mM CaCl2 in phosphate-
buffered saline (PBS) and split at a ratio of 1:3 to 1:6.
BAC Recombineering
BAC recombineering is described in the supplemental onlinedata.
Genetic Modification of hiPSCs
Genetic modification of hiPSCs is described in the supplemental
online data.
TaqMan Polymerase Chain Reaction Assay
TaqMan polymerase chain reaction (PCR) is described in the
supplemental online data.
Removal of PGK-Neo Cassette by Transient Creatinine-
Recombinase Expression
Removal of PGK-neo cassette by transient creatinine (Cre) recom-
binase expression is described in the supplemental online data.
Single-Nucleotide Polymorphism Array Analysis
The single-nucleotide polymorphism (SNP) array analysis is de-
scribed in the supplemental online data.
Karyotyping
Karyotyping is described in the supplemental online data.
Real-Time PCR and Real-Time Quantitative
Reverse Transcription-PCR
Real-time PCR and real-time quantitative reverse transcription
(RT)-PCR is described in the supplemental online data.
Flow Cytometry and Cell Sorting
Flowcytometry and cell sorting aredescribed in the supplemental
online data.
Immunostaining and Lectin Staining
Immunostaining and lectin staining are described in the
supplemental online data.
Embryoid Body-Based Differentiation Protocol
For embryoid body (EB) formation from hiPSCs/ESCs, a 10-cm
plate containing hiPSCs/ESCs at 70%–80% confluence was rinsed
with PBS and treatedwith CTK dissociation solution for 4minutes
at 37°C. The CTK dissociation solution was rinsed with PBS and
replacedwith EBmedium containing Dulbecco’smodified Eagle’s
medium (DMEM)/F12 plus GlutaMAX (Invitrogen) supplemented
with0.1mMnonessential aminoacids (Invitrogen), 1,000U/ml PS
(Invitrogen), 55 mM 2-mercaptoethanol (Invitrogen), and 20%
KSR. The cells were then scraped off with a cell scraper and dis-
tributed onto 6-cm plates coated with 0.2% gelatin to remove
the feeder cells. After 1 hour, the cells were washed with stage
1 medium containing DMEM/F12 plus GlutaMAX supplemented
with 500U/ml PS and 2% fetal bovine serum (HyClone, Logan, UT,
http://www.hyclone.com) [6] and transferred into low attach-
ment dishes (Sumitomo Bakelite Co., Ltd., Tokyo, Japan, http://
www.sumibe.co.jp) containing stage 1 medium with 100 ng/ml
recombinant human/mouse/rat activin A (R&D Systems, Minne-
apolis, MN, http://www.rndsystems.com) and 1 mM CHIR99021
(Axon Medchem BV, Groningen, The Netherlands, https://us.
axonmedchem.com). To differentiate cells toward the IM, EBs
on culture day 3were transferred onto 24-well plates coatedwith
Synthemax II (Corning, Corning, NY, http://www.corning.com).
The cells were then cultured with stage 2 medium (DMEM/F12
plus GlutaMAX, 0.1 mM nonessential amino acids, 500 U/ml
PS, 55mM2-mercaptoethanol, and 10% KSR) supplemented with
100 ng/ml recombinant human bone morphogenetic protein
(BMP) 7 (R&D Systems) and 1 mM CHIR99021. After 3 days (on
day 6), the medium was changed to the stage 2 medium supple-
mentedwith 1mMTTNPB (Santa Cruz Biotechnology, Santa Cruz,
CA, http://www.scbt.com) and 5 ng/ml transforming growth fac-
tor (TGF)-b1 (PeproTech, Rocky Hill, NJ, http://www.peprotech.
com) for stage 3 treatment, after which the cultures were
refreshed with new medium containing the same factors on
day8.Onday11, themediumwas switched to the stage2medium
supplemented with 5 ng/ml TGF-b1 and 0.5 mM dorsomorphin
homolog (DMH) 1 (Tocris Bioscience, Bristol, United Kingdom,
http://www.tocris.com) for stage 4 treatment. Subsequently,
the medium was refreshed with new medium and the above
factors every 3 days.
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Media Conditioned by Ureteric Bud Cells
Media conditioned by ureteric bud cells (UBCs) are described in
the supplemental online data.
Organ Culture Experiments With E11.5 Spinal Cord
or Metanephros
The organ culture experiments are described in the supplemental
online data.
Coculture of OSR1+SIX2+ Cells With NIH3T3 Fibroblasts
Expressing Wnt4
Coculture of OSR1+SIX2+ cells with NIH3T3 fibroblasts expressing
Wnt4 is described in the supplemental online data.
Graft Preparation and Implantation Into Epididymal Fat
Pads of Immunodeficient Mice
Graft preparation and implantation are described in the
supplemental online data.
Graft Preparation and Implantation Into
Immunodeficient Mice With Renal Disease
The Kyoto University Animal Care Committee approved all animal
experiments. For transplantation,OSR1+SIX2+ renal progenitor cells
(iPSC-RPs), OSR12SIX22 cells, OSR1+SIX22 cells, and OSR12SIX2+
cells obtained on culture days 25–28 were isolated by flow cytom-
etry sorting, split into spindle-shaped bottom low adhesion 96-well
plates (Sumitomo Bakelite) at a density of 1.03 105 cells per well
with UBC-conditioned media supplemented with 50 ng/ml BMP7
and 10 mM Y-27632 for 24 hours and incubated with UBC-
conditioned media supplemented with 50 ng/ml BMP7, 0.5 mM
BIO, and 10 mM Y-27632 for an additional 24 hours. Undifferenti-
ated hiPSCs (4A6C3-10)were split into spindle-shaped bottom, low-
adhesion, 96-well plates at a density of 1.03 105 cells per well with
primate ES cell media supplemented with 10 mM Y-27632 for 48
hours. After the cells werewashedwith saline to remove themedia,
15 cell aggregates (approximately 1.5 3 106 cells) of each type of
iPSC-RPs, OSR12SIX22 cells, OSR1+SIX22 cells, OSR12SIX2+ cells,
and undifferentiated iPSCs were transplanted into the kidney sub-
capsules of the immunodeficient mice (NOD.CB17-Prkdcscid/J) with
AKI.
The mouse AKI models were generated in a blind manner as
described previously [21–23]. In brief, 6-week-old male immuno-
deficient mice were anesthetized via isoflurane inhalation and
maintained at 37°C. After right nephrectomy through a flank in-
cision, an atraumatic microvascular clamp (Natsume Seisakusho,
Tokyo, Japan, http://www.nazme.co.jp) was used to occlude the
left renal artery for 40minutes. After releasing the clamp, the five
types of cellular aggregates were transplanted; the control mice
received a saline injection.
For transplantation into the renal parenchyma of the AKImice,
we injected 15 cell aggregates (approximately 1.5 3 106 cells) of
iPSC-RPs after the same pretreatment with UBC-conditioned me-
diumcontainingBMP7,BIO,andY-27632 into thecortexof thehost
kidney just after ischemia/reperfusion (I/R) injury through a slim
micropipette tip. The wound was sealed with Spongel (Astellas
Parma, Tokyo, Japan, http://www.astellas.com) immediately to
prevent hemorrhage.
The conditioned medium of OSR1+SIX2+ cells was generated
as previously reported [24]. In brief, 1 3 105 OSR1+SIX2+ cells
were culturedwith 100ml of serum-freeDMEM/F12 for 48 hours,
and the supernatant was separated from the cells by filtering
through a 0.22-mm filtration unit. We injected 200 ml of the con-
ditionedmedium i.p. onceperday fromday0 just after generating
the AKI to day 7.
The peripheral blood plasma was assayed for the blood urea
nitrogen (BUN) and Cre levels using theDRI-CHEM7000VZ instru-
ment (Fujifilm, Tokyo, Japan, http://www.fujifilmcom).
Renal Histopathology
After removing the renal tissue from the host mice, the kidneys
were fixed in 10% neutral buffered formalin and embedded in
paraffin. Thereafter, paraffin sections were sliced (3 mm) and
subsequently stained with hematoxylin and eosin, periodic
acid-Schiff, and Masson’s trichrome. Histological examinations
were performed by the CMIC Bioresearch Center Co., Ltd.
(Tokyo, Japan), for objective assessments. At least 10 nonover-
lapping fields in 1 entire section of each kidney samplewere ran-
domly examined using a 320 objective. The degree of tissue
damage in the kidney cortex and outer medulla was assessed
according to the commonly used and well-established method
for AKI [25–27]. In brief, we graded the extent of tubular necro-
sis, urinary casts, tubular dilatation, and loss of tubular borders
on a scale of 0 to 2, as follows: 0, none; 0.5, minimal; 1, mild; 1.5,
moderate; and 2, marked. Interstitial fibrosis was also graded
using the same category criteria.
Microarray Analysis
The microarray analysis is described in the supplemental online
data.
Multiplex Protein Detection
Multiplex protein detection is described in supplemental online
data.
Statistical Analysis
The data are shown as themean6 SEM or 95% confidence inter-
vals.We applied the Kruskal-Wallis test for comparisons between
the twogroups. For longitudinal data, themixed effectsmodel for
repeated measures was used for each dependent variable [28].
The model included the treatment group, time, and treatment-
by-time interaction as factors and random intercept for each sub-
ject, and the model parameters were estimated by restricted
maximum likelihood. The covariancematrixwasmodeled in com-
pound symmetry. The comparisons of interactions were formu-
lated by one degree of freedom contrasts between the mean
values for the groups. Multiple comparison type I error rate ad-
justmentwasbasedonaBonferroni-adjustedcriterionwitha type
I error rate of 0.05. All statistical analyses were performed using





To monitor and quantitatively evaluate the differentiation
of OSR1+SIX2+ renal progenitors from hiPSCs, we established
OSR1-GFP/SIX2-tdTomato double knock-in hiPSC lines using our
982 Cell Therapy Using hiPSC-Renal Progenitors
©AlphaMed Press 2015 STEM CELLS TRANSLATIONAL MEDICINE
previously reported gene targeting strategy [6]. We constructed
a BAC-based vector shown in Figure 1A. Becausemutations in the
SIX2 genewere identified as a possible cause of renal hypodyspla-
sia [29], a tdTomato reporter gene fused with the internal ribo-
some entry site (IRES) was knocked-in after a stop codon to
retain the intact SIX2 gene expression. The OSR1-GFP knock-in
hiPSC line, 3D45, which we previously generated, was used as
a parental line [6].Two clones, 4A6 and 4A61, were selected as
candidate homologous recombinants from approximately 300
drug-resistant clones by TaqMan quantitative PCR analyses per-
formed to detect the loss of a 39UTR region of the SIX2 gene,
which was replaced by an IRES-tdTomato-Neo cassette (Fig.
1B). The Neo cassette was then excised at the flanking loxP sites
by the transient expression of Cre recombinase, which was con-
firmed by genomic PCR (Fig. 1C).
We performed SNP array analyses to examine the copy num-
bers of the SIX2 gene [6] and found that the two clones had two
loci, and noncandidate clones, such as 4A77, showed three copies
(Fig. 1D). Thus, the analyses confirmed the generation of two
knock-in lines with homologous recombination. We then used
a G-banding analysis for the three clones after removing the
Neo cassette (4A6C3-10, 4A61C4-16, and 4A61C4-20) and found
that all three showed a normal karyotype (Fig. 1E).
Next, tdTomato-positive cellswere induced from4A6C3-10at
low efficiency (0.7%6 0.5%) by our EB-based IM differentiation
method [6] (Fig. 2A) and were isolated by flow cytometry for RT-
PCR analyses and immunostaining, which showed that only the
tdTomato-positive cells expressed SIX2 and indicated a correla-
tion between tdTomato and SIX2 expression (Fig. 2B, 2C). These
results suggested that the reporter lines could be used tomonitor
both OSR1+ and SIX2+ cells differentiated from hiPSCs.
Establishment of the Protocol for Inducing hiPSCs Into
OSR1+SIX2+ Cells
To establish protocols for the more efficient differentiation of
OSR1+SIX2+ renal progenitors from hiPSCs through OSR1+ IM cells,
we examined the effects of approximately 50 different growth fac-
torsand8,000smallmoleculeson theOSR1+ IMcells inducedbyour
EB-based IM differentiation method (data not shown). We previ-
ously reported that retinoic acid receptor (RAR) agonists efficiently
differentiated hiPSCs into IM cells [7]. Thus, the a-RAR agonist,
TTNPB, was added to the EB method, which more efficiently gen-
erated OSR1+ cells (data not shown). The screening of growth fac-
torsandchemicals revealed that thecombinationofBMP inhibitors
and TGF-b isoforms was the most potent treatment leading to
OSR1+SIX2+ cell induction (Fig. 3A, 3B). DMH1, a selective BMP an-
tagonist [30], more potently induced OSR1+SIX2+ cells than the
other BMP inhibitors we examined, including Noggin, dorsomor-
phin, and LDN-193189. Among the TGF-b isoforms, TGF-b1 was
the most efficient inducer. A selective TGF-b receptor 1 inhibitor,
SB431542, prevented the differentiation of OSR1+SIX2+ cells (Fig.
3B).We finally establishedan optimal protocol to induce the differ-
entiation of OSR1+SIX2+ cells from hiPSCs-derived IM cells using
a combined treatment with 1 mM TTNPB, 5 ng/ml TGF-b1, and
0.5 mM DMH1 (Fig. 3A).
By periodically monitoring the OSR1+ and SIX2+ cells during
the course of differentiation by flow cytometry and 4A6C3-10
cells, we found a gradual increase in the frequency of OSR1+SIX2+
cells up tomore than30%oncultureday28 (Fig. 3C; supplemental
online Fig. 1), consistent with the results of the quantitative
RT-PCR analyses (Fig. 4A).We found bothGFP and tdTomato fluo-
rescence signals in almost all the isolated OSR1+SIX2+ cells by aug-
menting the signals using anti-GFP and anti-DsRed immunostaining,
which also confirmed the induction rate of the OSR1+SIX2+ cells
(Fig. 3C).
Different hiPSC/ESC lines have been shown to vary in their dif-
ferentiation potential [17, 31]. We examined our induction pro-
tocol for OSR1+SIX2+ cells with 18 different hiPSC/ESC lines
[15–20] (supplemental online Fig. 2). Although theexpression lev-
els of OSR1 and SIX2 differed among the cell lines, our protocol
more potently induced the expression of the two genes in multi-
ple lines compared with 4A6C3-10.
We next examined the gene expression profiles of renal lin-
eagemarkers in our hiPSC differentiation culture. As expected,
the treated EBs expressed BRACHYURY and TBX6, markers for
posterior nascent mesoderm, which has been reported to dif-
ferentiate into IM [32], at stages 1 and 2 andOSR1 after stage 2.
Thereafter, the expression of metanephric mesenchyme
markers, WT1, PAX2, and SIX2, and the posterior HOX genes
was observed (Fig. 4A). The OSR1+SIX2+ cells isolated by flow
cytometry sorting on day 28 also expressed other nephron pro-
genitormarkers, including CITED1, EYA1, SALL1, ITGA8, CDH11,
GDNF, and HOXD11, and expression of a stromal marker,
FOXD1, and a nephric duct marker, HOXB7, was not detected
(Fig. 4B). The OSR1+SIX2+ cells were also positive for PAX2
and WT1, but not for an early nephron marker CDH6, as ana-
lyzed using immunocytochemistry (Fig. 4C). Not all cells were
WT1+, suggesting that the OSR1+SIX2+ cells generated by our
EB-based differentiation protocol are heterogeneous. No
marker gene expression for other nonrenal mesoderm, endo-
derm, or ectoderm tissueswas detected in theOSR1+SIX2+ cells
on day 28, indicating that these cells are renal lineage-
committed cells (supplemental online Fig. 3).
hiPSC-Derived OSR1+SIX2+ Cells Have Developmental
Potential as Tubulogenic Renal Progenitors
Because Six2+ nephron progenitors contribute tomultiple epithe-
lial cell types constituting nephrons [1, 2], we assessed the devel-
opmental potential of hiPSC-derived OSR1+SIX2+ cells isolated on
day 28 using various methods. First, when the OSR1+SIX2+ cell
aggregates without additional treatments were cocultured with
mouse embryonic spinal cord and NIH3T3 fibroblasts expressing
Wnt4, awell-known inducer of themetanephricmesenchyme for
7 days [1, 33], the aggregates did not develop tubule-like struc-
tures (data not shown).
We then considered the pretreatment of OSR1+SIX2+ cells be-
fore the cocultures. BMP7 is required for the epithelialization of
Six2+ nephron progenitors by Wnt9b [34], and treatment with
BIO, a glycogen synthase kinase-3 inhibitor, mimics the action of
Wnt9b in theprocessofnephrogenesis [35].Aprevious studydem-
onstrated thatmultiple factors contained in the conditionedmedia
of UBC lines protect renal progenitors from apoptosis [36, 37].
Therefore, OSR1+SIX2+ cells were treated in UBC-conditioned me-
dia supplemented with 50 ng/ml BMP7 and 0.5mMBIO, which in-
creased the expression of CDH6 (supplemental online Fig. 4). Next,
we cocultured the treated OSR1+SIX2+ cell aggregates with mouse
embryonic spinal cord tissue in an organ culture setting for 7 days.
As a result, the aggregates developed tubular structures that were
positive for proximal renal tubule markers, Lotus tetragonolobus
lectin (LTL) and CDH6, a marker of polarized epithelia, LAMININ,
Toyohara, Mae, Sueta et al. 983
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and an epithelial marker, CDH1, in all 17 organ culture samples ex-
amined (Fig. 5A; supplemental online Fig. 5A). The structures con-
sisting of cells positive for glomerular podocytemarkers, WT1 and
PODOCALYXIN, but not mature podocyte markers, NEPHRIN and
PODOCIN, were formed at a low frequency (3 of 17 organ culture
samples, 17.6%), suggesting that they might be rather primitive
glomerular lineage cells (supplemental online Fig. 5B) [38]. Tubular
structuresstainedwithdistal tubulemarkers, suchasPAX2,CLC-K2,
and CALBINDIN, were not observed (data not shown). In contrast,
OSR12SIX22cell aggregatesdidnot reconstitutetubularstructures
and had disappeared by day 7 (Fig. 5A). Similar results were
obtained by coculturing the treated OSR1+SIX2+ cell aggregates
with NIH3T3 fibroblasts expressing Wnt4, which showed the for-
mation of LTL+LAMININ+ proximal tubule-like structures in all 20
Figure 1. The generation of OSR1-GFP/SIX2-tdTomato double knock-in hiPSC lines. (A): A schematic representation of the targeting strategy
using BAC-based vectors to produce OSR1-GFP/SIX2-tdTomato double knock-in hiPSC lines. The black boxes represent two exons of the SIX2
gene. (B):TheTaqManquantitative polymerase chain reaction (PCR) analyses of genomicDNA fromthedrug-resistant lines and theparental line
(201B7). Note that a value of 1 indicates 2 intact SIX2 loci, and 0.5 suggests 1 intact and 1 targeted locus. 4A157 is a drug-resistant clonewithout
homologous recombination. The primer pair indicated in (A) (red bars) was used. (C):Genomic PCRwas used to confirm the removal of the Neo
cassette by Cre recombination. The primer pair indicated in (A) (black bars) was used. (D): The CN of SIX2 gene loci was analyzed by determining
thenumber of single-nucleotide polymorphisms (SNPs) in the3hiPSC lines: 4A6, 4A61, and4A77. 4A77 is adrug-resistant transgenic linewithout
homologous recombination. The reddots and y-axis represent the signal intensity of eachSNPprobe ineachpanel, and theCNs (black lines)were
detected using a hiddenMarkovmodel-based algorithm implemented in the CNAG/AsCNAR software program (Cancer Genomics Project, Uni-
versity of Tokyo, Tokyo, Japan). Theblue lines represent themoving averageof total CNs. (E):Normal karyotypeswere found for the3OSR1-GFP/
SIX2-tdTomato double knock-in hiPSC lines (4A6C3-10, 4A61C4-16, and 4A61C4-20) in which the Neo cassette was excised at the flanking loxP
sites by transient expression of Cre recombinase. Abbreviations: bp, base pairs; BAC, bacterial artificial chromosome; CN, copy number; Cre,
creatinine; GFP, green fluorescent protein; hiPSC, human inducible pluripotent stem cell; IRES, internal ribosome entry site.
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cultures examined andWT1+PODOCALYXIN+ immature glomerulus-
like structures in 3 of 20 cultures (15.0%; Fig. 5B).
When we cocultured the treated OSR1+SIX2+ cells with dis-
sociated E11.5 mouse metanephric cells in organ cultures [6,
39], we found some of the human CDH6+ cells integrated into
mouse Cdh6+ structures in 5 of 13 samples examined (38.5%),
although no C- or S-shaped bodies were clearly identified. The
OSR1+SIX2+ cells also contributed to LTL+LAMININ+ proximal
tubule-like structures within the mouse metanephric tissues
in 7 of 16 samples (43.8%; Fig. 5C). When cocultured with the
mouse metanephric cells, the OSR12SIX22 cells were not inte-
grated into themouse tissues and insteadhad formed separated
cell aggregates (data not shown). Furthermore, when trans-
planted into the epididymal fat pads of the immunodeficient
mice (NOD.CB17-Prkdcscid/J) [6], the treated OSR1+SIX2+ cells
formed LTL+LAMININ+ proximal tubule-like structures in vivo
in two of the four grafts examined (Fig. 5D). These results
suggest that the OSR1+SIX2+ cells generated from hiPSCs have
developmental potential as renal progenitors to mainly form
proximal tubule-like structures, although they are not as compe-
tent as the nephron progenitors in embryos.
Transplantation of hiPSC-Derived Renal Progenitors
Ameliorates Renal Injury in a Mouse Model of AKI
We next examined the therapeutic potential of hiPSC-derived
tubulogenic renal progenitors for AKI and transplanted the cellu-
lar aggregates of OSR1+SIX2+ cells purified on days 25–28, which
were pretreated with UBC-conditionedmedia, BMP7 and BIO, in-
to the kidney parenchyma of mice with AKI induced by I/R injury
just after the injury. Consequently, some OSR1+SIX2+ cells were
integrated into the host kidneys and then differentiated into cells
positive for a proximal tubular marker LTL within 2 weeks after
transplantation (supplemental online Fig. 6). However, the trans-
plantation did not result in any obvious beneficial effects on renal
function (data not shown).
We then considered the therapeutic possibility of the para-
crine effects induced by hiPSC-derived renal progenitors for AKI
and transplanted the treated OSR1+SIX2+ cell aggregates into
the renal subcapsule in the I/R model mice to allow for the ad-
ministration of a larger number of progenitor cells without caus-
ing any additional surgical damage to the host renal tissues. We
observed that the transplanted hiPSC-derived renal progenitors
did not differentiate into tubular structures normigrate into the
host kidney (supplemental online Fig. 7). However, the renal
functional parameter values (BUN and Cre levels) were signifi-
cantly lower in the mice transplanted with hiPSC-derived renal
progenitors than in the control mice treated without cell trans-
plantation (saline) or the mice transplanted with undifferenti-
ated hiPSCs at 2 days after I/R injury (Fig. 6A). Furthermore,
histological analyses performed on day 3 after transplantation
revealed that the renal parenchymal areaswith tubular necrosis,
urinary casts, and tubular dilatationwere significantly smaller in
the mice treated with hiPSC-derived renal progenitors than in
the saline group (supplemental online Fig. 8A, 8B). We next
compared the therapeutic effects of all four induced cell popu-
lations (OSR12SIX22, OSR1+SIX22, OSR12SIX2+, and OSR1+SIX2+
cells) and found that only the OSR1+SIX2+ cell population signifi-
cantly reduced both BUN and Cre values on day 2, although the
OSR1+SIX22 population decreased only the Cre values on day 8
with statistical significance, which suggests that the therapeutic
effectsonkidney injuryarespecific toOSR1+SIX2+ renalprogenitors
(supplemental online Fig. 9).
Histological analyses performedon day 12 after transplanta-
tion revealed that the areas of kidney injury with tubular necro-
sis, urinary casts, tubular dilatation, loss of tubular borders, and
interstitial fibrosis were significantly smaller in themice treated
with hiPSC-derived OSR1+SIX2+ renal progenitors than in the sa-
line group, even after the recovery of the renal function param-
eters (Fig. 6B, 6C; supplemental online Fig. 10A). Anti-a-smooth
muscle actin immunostaining also revealed that the areas of fi-
brosis were smaller in the mice treated with the OSR1+SIX2+ re-
nal progenitors than in the saline group (supplemental online
Fig. 10B). As reported previously, histological changes and fibro-
sis are important markers indicating the risk of developing late
renal failure even when the BUN levels do not differ at the AKI
stage [40]. These findings therefore suggest that cell therapy us-
ing hiPSC-derived renal progenitors ameliorates the degree of
Figure 2. Confirmation of the ability of OSR1-GFP/SIX2-tdTomato
double knock-in human inducible pluripotent stem cell lines to mon-
itor SIX2 expression. (A): The flow cytometric analyses of tdTomato-
positive cells on culture day 19 induced with or without the factors
used in our previously reported differentiation protocol for the inter-
mediate mesoderm [6]. The data from three independent experi-
ments are presented as the mean 6 SEM (n = 3). (B): The results
of the reverse transcription-polymerase chain reaction analyses of
the tdTomato-positive and tdTomato-negative cell populations iso-
lated on day 19 shown in (A). (C): Immunostaining using antibodies
against SIX2 on the tdTomato-positive and tdTomato-negative cells
isolated on day 19. Alexa Fluor 647 was used as the secondary anti-
body to eliminate any overlapwith theGFP or tdTomato signals. Scale
bars = 50 mm. Abbreviations: APC, allophycocyanin; GFP, green fluo-
rescent protein; Tx, treatment with factors described in [6].
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renal tissue damage, including interstitial fibrosis, which indi-
cates the risk of chronic tissue damage.
The therapeutic effects of the renal subcapsular transplanta-
tion of hiPSC-derived renal progenitors are thus thought to be
mainly due to paracrine effects.We identifiedmultiple factors se-
creted from OSR1+SIX2+ renal progenitors, such as angiopoietin
(ANG)-1, vascular endothelial growth factor (VEGF)-A, and hepa-
tocyte growth factor (HGF), that are known to be renoprotective
factors produced by mesenchymal stem cells (Fig. 7) [41]. These
results suggest that the renal subcapsular transplantation of
hiPSC-derived OSR1+SIX2+ renal progenitors could therefore be
a potentially effective therapeutic option for AKI.
DISCUSSION
In the present study, we established a method to induce the dif-
ferentiation of hiPSCs into tubulogenic renal progenitors, which
subsequently ameliorated renal injury in a mouse model of AKI
induced by I/R injury. Although several studies have reported re-
nal progenitor induction from hESCs/iPSCs [14, 32, 42–44], few
Figure 3. The establishment ofmethods for differentiating human iPSCs into OSR1+SIX2+ cells. (A): The differentiationmethod used to generate
OSR1+SIX2+ cells with embryoid body-based three-dimensional cultures. (B): The differentiation efficiencies of OSR1+, SIX2+, and OSR1+SIX2+ cells
were analyzed by flow cytometry on culture day 28. The treatments at stages 1, 2, and 3 were the same as those used in A. The factors and their
concentrations used at stage 4 were as follows: 0.5 mMDMSO as a negative control, 5 ng/ml TGF-b1, 5 ng/ml TGF-b2, 5 ng/ml TGF-b3, 0.5 mM
DMH1, 100 ng/ml Noggin, 0.5 mM DMH1, 0.5 mM LDN-193189, 50 mM IDE2, and 10 mM SB431542. Noggin, DMH1, LDN, and DMH1 are BMP
inhibitors. IDE2 is a small molecule that activates TGF-b signaling. The data from five independent experiments are presented as the mean 6
SEM (n = 5). (C): The periodic differentiation pattern ofOSR1+SIX2+ cells was analyzed by flow cytometry. Upper: The two-dimensional distribution
of the cell populations.Middle: The results of the time course analyses. The data from five independent experiments are presented as themean6
SEM (n = 5). Day 1 indicates culture day 1 before treatment. Day 3 indicates day 3 after stage 1 treatment. Day 6 indicates day 6 after stage 2
treatment. On days 6–28, the cells were treated with stage 3 and 4 treatment or with DMSO at stages 3 and 4 (negative control). Representative
anti-GFP and anti-DsRed (tdTomato) immunostaining images of OSR1+SIX2+ renal progenitors isolated on day 28 are shown in the lower panels.
Scale bars = 50 mm. Abbreviations: BMP, bone morphogenetic protein; DMEM, Dulbecco’s modified Eagle’s medium; DMH1, dorsomorphin
homolog 1; DMSO, dimethyl sulfoxide; FBS, fetal bovine serum; GFP, green fluorescent protein; KSR, knockout serum replacement; PS, penicillin/
streptomycin; TGF, transforming growth factor; Tx+, treatment with stage 3 and 4 treatment; Tx2, treatment with negative control.
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reports have thus far demonstrated the therapeutic effects of cell
therapy using these induced renal cells. Only one recent report
showed that hiPSC-derived renal progenitors integrated into
the kidney in another type of AKI mouse model induced by cis-
platin administration ameliorated renal injury after transplanta-
tion via the tail vein [14]. However, it is not clear whether the
integration of hiPSC-derived renal progenitors into the host kid-
ney tissues or the trophic effects of factors secreted from the pro-
genitorsmainly contribute to the observed therapeutic effects on
AKI and whether hiPSC-derived renal progenitors themselves ex-
ert these effects, because all hiPSC-derived differentiated cells
containing renal progenitors and other cell types were trans-
planted in that study. In the present study, we havemore directly
and strictly demonstrated the therapeutic potential of hiPSC-
derived renal progenitors by transplanting the purified progeni-
tor population using an OSR1-GFP/SIX2-tdTomato double
knock-in hiPSC line and flow cytometry sorting. Hence, the renal
progenitors generated in our study might have an advantage for
clinical application. The results from both the recent report and
the present study suggest the feasibility of cell therapy using
hiPSC-derived renal progenitor cells to treat AKI. Although the
recent report involved the systemic administration of hiPSC-
derived renal progenitors via the tail tip vein, we found that renal
subcapsular transplantation, but not parenchymal injection, of
hiPSC-derived renal progenitors produced therapeutic benefits
in a mousemodel of AKI. This observation suggests that the renal
subcapsular transplantation of hiPSC-derived renal progenitors
might be a suitablemethod for providing cell therapy against AKI.
In the present study, we have confirmed that hiPSC-derived
renal progenitors transplanted into the renal subcapsule exerted
therapeutic effects without migrating inside the host kidney,
which suggests that some secreted, not cell-bound, factors de-
rived from the progenitor cells working as trophic factors are
mainly responsible for the observed therapeutic effects on AKI.
Furthermore, we identified multiple growth factors secreted
from hiPSC-derived OSR1+SIX2+ cells that have been shown to
be renoprotective factors, such as ANG-1, VEGF-A, and HGF
(Fig. 7) [41]. However, the systemic administration of the culture
supernatant of hiPSC-derived OSR1+SIX2+ cells, which is believed
to contain the above trophic factors, via injection into the perito-
neal cavity in the AKI mice did not produce a therapeutic effect
against kidney injury (supplemental online Fig. 11). When these
Figure 4. The expression of renal lineage marker genes in the differentiation culture of human induced pluripotent stem cells (hiPSCs) into
OSR1+SIX2+ renal progenitors. (A): The time course analyses of mRNA expression in the differentiation culture. The graphs indicate the expres-
sion of each transcript relative to b-ACTIN.OCT3/4 andNANOG are markers for undifferentiated hiPSCs, BRACHYURY and TBX6 aremarkers for
posterior nascent mesoderm,OSR1 is a marker for intermediate mesoderm,WT1, PAX2, SIX2,HOXA10, and HOXA11 are markers for the meta-
nephric mesenchyme. The data from three independent experiments are presented as the mean6 SEM (n = 3). (B): The expression of marker
genes for nephron progenitors in OSR1+SIX2+ cells differentiated from an OSR1-GFP/SIX2-tdTomato double knock-in hiPSC line, 4A6C3-10, on
cultureday28. (C): Immunostaining imagesofOSR1+SIX2+ cells isolatedonday28against SIX2, PAX2,WT1, andCDH6. (B, C):Representativedata
obtained from three independent experiments shown. Scale bars = 50 mm.
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Figure 5. Developmental potential of OSR1+SIX2+ renal progenitors to differentiate into renal lineage cells or tissues. (A): The presentedmac-
roscopic views show the aggregates ofOSR12SIX22 cells on culture day5 (upper left) andOSR1+SIX2+ cells onday7 (upper right) coculturedwith
E11.5mouse spinal cord tissue in organ cultures. Lower panels: Immunostaining images of the histological sections of theOSR1+SIX2+ cell aggre-
gates after 7 days of coculturewith spinal cord tissue. LTL is amarker of the proximal renal tubules; LAMININ, amarker of the polarized epithelia;
CDH1, an epithelial marker; CDH6, an early proximal tubulemarker. (B): Coculture experiments with NIH3T3 fibroblasts expressingWnt4.Mac-
roscopic views of the aggregates of OSR12SIX22 cells on day 5 (upper left) and OSR1+SIX2+ cells on day 7 (upper right) and immunostaining
images of the histological sections of the OSR1+SIX2+ cell aggregates after 7 days of coculture (lower). Note that the lower left two panels in (A)
and (B) are of the same sections. (C): Immunostaining images of the organ culture of the OSR1+SIX2+ cells and E11.5 metanephric cells. (D):
Immunostaining images of the OSR1+SIX2+ cell aggregates transplanted into the epididymal fat pads of the immunodeficient mice (NOD.
CB17-Prkdcscid/J) after 30 days of transplantation. Scale bars = 50 mm. Abbreviations: AG, OSR12SIX22 or OSR1+SIX2+ cell aggregate; HuNu,
human nuclei; LTL, Lotus tetragonolobus lectin; SP, spinal cord.
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Figure 6. Cell therapy using human iPSC (hiPSC)-derived renal progenitors for themouse acute kidney (AKI) injury models. (A): The time course
analyses of the BUN and plasma Cre levels in the I/R AKImice that received the renal subcapsular transplantation of hiPSC-derived renal progen-
itors (n=6; iPSC-RPs, triangle), undifferentiatedhiPSCs (n=7; iPSCs, square),or saline (n=11;circle). Statistical significanceat thep, .05 levelafter
multiple testing adjustment: ppp, p, .001 versus saline; ††, p, .01 versus iPSCs; †††, p, .001 versus iPSCs. Least square mean and 95% con-
fidence intervalswereestimatedaccordingto themixedeffectsmodel for repeatedmeasures. (B):Sectionsof representativekidney samples from
the hostmice that received transplantation of iPSC-RPs, iPSCs, or salinewere stainedwith HE, PAS, orMT on day 12 after I/R and transplantation.
Representative findings of tubular necrosis, urinary casts, tubular dilatation, loss of tubular borders, and interstitial fibrosis in each treatment
groupare shown. Thearrows indicate the representativeareaof each finding. Scalebars =20mm. (C):Histological scoringof the areaswith tubular
necrosis, urinary casts, tubular dilatation, loss of tubular borders and interstitial fibrosis and total scores in the host kidneys on day 12 after I/R
and transplantation (n = 5 for iPSC-RPs, n = 7 for iPSCs, n = 7 for saline). p, p, .05 versus saline; †, p, .05 versus iPSCs. The data are presented as
themean6 SEM in (A) and (C). Abbreviations: BUN, blood urea nitrogen; Cre, creatinine; HE, hematoxylin and eosin; I/R, ischemia/reperfusion;
iPSC, induced pluripotent stem cell; iPSC-RP, OSR1+SIX2+ renal progenitor cells; MT, Masson’s trichrome; PAS, periodic acid-Schiff.
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data are taken together, we assume that some growth factors
secreted from the renal progenitors might contribute to the
noted therapeutic effects at concentrationshigher thanacertain
therapeutic threshold. It is therefore suggested that the renal
subcapsular transplantation of progenitor cells is required to
deliver these concentrated factors to the host kidney tissues
and thus obtain therapeutic effectiveness. In addition to growth
factors, other candidate therapeutic factors secreted from the re-
nal progenitors could include extracellular vesicles/microvesicles,
which have been reported to exert therapeutic effects on AKI
[45, 46].
In an attempt to elucidate the mechanisms of action of
paracrine factors, we also examined the apoptosis and prolif-
eration of cells in the host kidney on day 3 after I/R injury
and cell transplantation, when the degree of renal damage
had reached a peak, using a terminal deoxynucleotidyl trans-
ferase dUTP nick-end labeling assay and proliferating cell nu-
clear antigen staining, respectively. However, no significant
differences were found in the number of apoptotic or proliferat-
ing cells between the mouse group transplanted with hiPSC-
derived OSR1+SIX2+ progenitor cells and the control group that
received saline (supplemental online Fig. 8C). Additional studies
are thus needed to elucidate the mechanisms of action under-
lying the trophic effects of hiPSC-derived renal progenitors,
which might also contribute to the development of novel thera-
peutic drugs for AKI.
However, the hiPSC-derived OSR1+SIX2+ cells generated in
the present study had limited developmental competence as re-
nal progenitors, because they differentiatedmainly into proximal
tubular cells, not glomerular podocytes or distal tubular cells. The
renal progenitors induced in other studies showed developmen-
tal potential to form glomerulus-like [32] and distal renal tubule-
like [32, 42] structure, in addition to the proximal tubules. These
differences in developmental competence might derive from the
differences in the differentiation protocol.
One of the common principles of previously published differ-
entiation protocols and the current protocol for generating renal
progenitors is that they each aim to mimic the developmental
process that occurs in embryos, first differentiating ESCs/iPSCs in-
to the primitive streak ormesendoderm, then the IM, followed by
eventual nephron progenitor induction, although one report
addedmore developmental steps in their differentiation protocol
[32]. When our protocol is compared with previously reported
protocols, major differences emerge, including the factors used
at the induction step of nephron progenitors. Some reports
treated the cells with fibroblast growth factor (FGF)-2 or FGF-9,
because these factors have been shown to be expressed in the
IM and involved in the formation and maintenance of the meta-
nephric mesenchyme in mouse embryos [14, 32, 42–44, 47–50].
The presence or absence of these factors in the differentiation
protocol could lead to differences in the characteristics of the
induced renal progenitors.
In contrast, we identified BMP inhibitors and TGF-b isoforms
as factors for inducing OSR1+SIX2+ renal progenitors from
hiPSCs-derived IM cells by performing an unbiased screening
of growth factors and small molecules. These factors were not
reported to induce renal progenitors in previous studies [14,
32, 42–44]. However, consistent with our results, in one study,
the phosphorylation of Smad1, a molecule downstream of BMP
signaling, was strongly detected in the posterior primitive streak
at stage 7 and subsequently diminished in the IM at stage 10 in
chick embryos, although phosphorylation was also detected in
the lateral plate mesoderm. In addition, the Smad1 signal was
not activated in the nephrogenic mesenchyme, but rather in
the nephric duct at stage 14 [51].
It has been reported that the TGF-b2 secreted by UBC
enhances the epithelialization of the mouse metanephric mes-
enchyme in explant cultures [52]. It has also been suggested that
the metanephric mesenchyme changes the composition of the
extracellular matrix and induces cellular aggregation in the cap
mesenchyme in response to TGF-b signals [53]. Although addi-
tional studies are needed to elucidate the exact role of BMP
and TGF-b signals in early renal differentiation, these findings
and our results suggest the involvement of BMP inhibition and
TGF-b activation in the induction of renal progenitors from the
IM. Screening for growth factors and small molecules using an
unbiased high-throughput method can serve as a powerful tool
for identifying novel factors that induce the differentiation of
ESCs/iPSCs into renal lineages and elucidating the mechanisms
of kidney development.
Figure 7. OSR1+SIX2+ renal progenitors secrete the growth factors known to be renoprotective factors. (A): The RNA expression of renopro-
tective factors in the iPSC-RPs compared with that observed in the iPSCs using a microarray analysis. (B): Protein section of renoprotective
factors analyzed by the human magnetic luminex screening assay in medium only (medium) and cell culture supernatant of iPSCs and iPSC-
RPs. The data from 3 independent experiments are presented as the mean 6 SEM (n = 3). Note that the secretion levels of ANG-1, VEGF-A,
and HGF in the medium and those of ANG-1 and HGF in the iPSCs were so low that the histogram bars are at the baseline level. Abbreviations:
ANG-1, angiopoietin 1; CCL2, C-C motif chemokine 2; CXCL12, C-X-C motif chemokine 12; FGF-9, fibroblast growth factor 9; HGF, hepatocyte
growth factor; IGF1, insulin-like growth factor 1; IGF2, insulin-like growth factor 2; iPSCs, inducible pluripotent stem cells; iPSC-RPs, OSR1+SIX2+
renal progenitor cells; TGF-B2, transforming growth factor-b2; VEGF-A, vascular endothelial growth factor A; VEGF-C, vascular endothelial
growth factor C; VEGF-D, vascular endothelial growth factor D.
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Additional manipulation and optimization of the differentia-
tion protocol, including the selection of inducing factors, as well
as further elucidation of themechanisms of kidney development,
are needed to generate nephron progenitors and renal lineage
cells with more potent developmental and/or therapeutic com-
petencies from ESCs/iPSCs.
CONCLUSION
We have developed a method for inducing the differentiation of
hiPSCs into tubulogenic renal progenitors and subsequently dem-
onstrated that the renal subcapsular transplantation of these
hiPSC-derived progenitor cells ameliorates renal injury in an
AKI mouse model induced by I/R injury. Furthermore, we have
demonstrated the therapeutic efficacy of cell therapy with renal
cells generated from hiPSCs, suggesting that hiPSC-derived renal
lineage cells might be used to develop regenerative therapies for
kidney diseases.
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